Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
The present invention provides methods for treating a cancer in a subject and for inhibiting tumor growth, metastasis or a dihydrorotate oxygenase enzyme activity of a tumor or cancer cell. At least one trisubstituted benzotriazole derivative with the formula (I) is administered to the subject or is contacted with the cancer cell. Compounds of formula (I) have substituents R 1 , R 2 and R 3 which have the meanings given in the specification, and pharmaceutically acceptable salts thereof.
1. A method of treating a cancer selected from acute myeloid leukemia, multiple myeloma, B-prolymphocytic leukemia, non-Hodgkin's lymphoma, diffuse large B cell lymphoma, anaplastic large cell lymphoma, mantle cell lymphoma, triple negative breast cancer, melanoma, prostate cancer, and cancer of the esophagus, in a subject, comprising administering to the subject a therapeutically effective amount of Compound l represented by the following structural formula:
2. The method according to claim 1 , wherein the cancer is acute myeloid leukemia.
3. The method according to claim 1 , wherein the cancer is multiple myeloma.
4. The method according to claim 1 , wherein the cancer is B-prolymphocytic leukemia.
5. The method according to claim 1 , wherein the cancer is non-Hodgkin's lymphoma.
6. The method according to claim 1 , wherein the cancer is diffuse large B cell lymphoma.
7. The method according to claim 1 , wherein the cancer is anaplastic large cell lymphoma.
8. The method according to claim 1 , wherein the cancer is mantle cell lymphoma.
9. The method according to claim 1 , wherein the cancer is triple negative breast cancer.
10. The method according to claim 1 , wherein the cancer is melanoma.
11. The method according to claim 1 , wherein the cancer is prostate cancer.
12. The method according to claim 1 , wherein the cancer is cancer of the esophagus.